Back to search

France· FR:63467355

TIXTAR 550 mg, comprimé pelliculé

A medicinal product containing rifaximine, registered in France by ALFASIGMA FRANCE, on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedTIXTAR 550 mg, comprimé pelliculéATC—REGISTER NO.FR:63467355PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
RIFAXIMINE
Manufacturer
ALFASIGMA FRANCE
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930009666
    plaquette(s) PVC polyéthylène PVDC aluminium de 56 comprimé(s)
    EUR 195.45

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Rifaximine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rifaximine products

Authorised across Europe · EMA

The same active substance is authorised in 20 EEA countries. Names it is sold under:

  • Austria · Colidimin, Refero
  • Belgium · Targaxan, Tixteller
  • Czechia · Normix
  • Germany · Rifaxan, Tixteller
  • Denmark · Faxinorm, Xifaxan
  • Spain · Spiraxin, Tixtar
  • Finland · Targaxan, Xifaxan
  • United Kingdom (Northern Ireland) · Normicron, Rifaximin
  • Greece · Rifacol
  • Hungary · Normix, Refero
  • Ireland · Rifaximin Alfasigma, Targaxan
  • Italy · Flonorm, Normix
  • Luxembourg · Refero, Targaxan
  • Netherlands · Tixteller, Xifaxan
  • Norway · Xifaxan
  • Poland · Tixteller, Xifaxan
  • Portugal · Refero, Xifaxan
  • Romania · Normix, Tixteller
  • Sweden · Xifaxan
  • Slovakia · Normix, Refero

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/04c6cf76-b1cb-4128-937f-04cafa92154a
GET /v1/drugs/04c6cf76-b1cb-4128-937f-04cafa92154a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "63467355",
  "date_amm": "2015-02-25",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "RIFAXIMINE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about rifaximine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.